Matching articles for "Clostridioides difficile"
Vonoprazan (Voquezna) for Nonerosive GERD
The Medical Letter on Drugs and Therapeutics • October 14, 2024; (Issue 1713)
The potassium-competitive acid blocker vonoprazan
(Voquezna – Phathom), which was approved earlier
for treatment of erosive esophagitis, has now been
approved by the FDA for relief of heartburn...
The potassium-competitive acid blocker vonoprazan
(Voquezna – Phathom), which was approved earlier
for treatment of erosive esophagitis, has now been
approved by the FDA for relief of heartburn associated
with nonerosive gastroesophageal reflux disease
(GERD) in adults. Vonoprazan is also available
copackaged with amoxicillin (Voquezna Dual Pak) and
with amoxicillin and clarithromycin (Voquezna Triple
Pak) for treatment of Helicobacter pylori infection.
Cefepime/Enmetazobactam (Exblifep) for Complicated Urinary Tract Infections
The Medical Letter on Drugs and Therapeutics • July 22, 2024; (Issue 1707)
The FDA has approved Exblifep (Allecra), a fixed-dose
combination of the cephalosporin cefepime and the
beta-lactamase inhibitor enmetazobactam, for IV
treatment of adults with complicated urinary...
The FDA has approved Exblifep (Allecra), a fixed-dose
combination of the cephalosporin cefepime and the
beta-lactamase inhibitor enmetazobactam, for IV
treatment of adults with complicated urinary tract
infections (cUTIs), including pyelonephritis, caused
by designated susceptible microorganisms (see
Spectrum of Activity). Exblifep is the first product that
contains enmetazobactam to be approved in the US.
Vonoprazan (Voquezna) for Erosive Esophagitis
The Medical Letter on Drugs and Therapeutics • December 25, 2023; (Issue 1692)
The FDA has approved vonoprazan (Voquezna –
Phathom), a potassium-competitive acid blocker, for
healing and maintenance of healing of all grades of
erosive esophagitis and relief of associated heartburn in...
The FDA has approved vonoprazan (Voquezna –
Phathom), a potassium-competitive acid blocker, for
healing and maintenance of healing of all grades of
erosive esophagitis and relief of associated heartburn in adults. Vonoprazan is also available copackaged
with amoxicillin (Voquezna Dual Pak) and with
amoxicillin and clarithromycin (Voquezna Triple Pak)
for treatment of Helicobacter pylori infection in adults.
Live Fecal Microbiota Oral Capsules (Vowst) for Prevention of CDI Recurrence
The Medical Letter on Drugs and Therapeutics • May 29, 2023; (Issue 1677)
The FDA has approved Vowst (Seres Therapeutics/Nestle HealthScience), an oral capsule containing live
fecal microbiota spores, for prevention of additional
recurrences of Clostridioides difficile infection...
The FDA has approved Vowst (Seres Therapeutics/Nestle HealthScience), an oral capsule containing live
fecal microbiota spores, for prevention of additional
recurrences of Clostridioides difficile infection (CDI)
in adults. Vowst is the first orally administered
microbiota-based treatment to be approved for
this indication. A rectally-administered live fecal
microbiota-based suspension (Rebyota) was
approved in 2022 for the same indication. Neither
product is approved for acute treatment of CDI.
Treatment of Common Respiratory Tract Infections
The Medical Letter on Drugs and Therapeutics • April 17, 2023; (Issue 1674)
Most respiratory tract infections are caused by
viruses. Bacterial respiratory tract infections are
usually treated empirically with antibiotic therapy
that targets the most probable causative...
Most respiratory tract infections are caused by
viruses. Bacterial respiratory tract infections are
usually treated empirically with antibiotic therapy
that targets the most probable causative pathogens.
Recommended antibiotic regimens for outpatient
treatment of some common respiratory tract
infections are listed in Table 1 for adults and Table 2
for children.
Live Fecal Microbiota (Rebyota) for Prevention of CDI Recurrence
The Medical Letter on Drugs and Therapeutics • March 6, 2023; (Issue 1671)
The FDA has approved Rebyota (Ferring), a rectally-administered,
live fecal microbiota suspension, for
prevention of additional recurrences of Clostridioides
difficile infection (CDI) following antibiotic...
The FDA has approved Rebyota (Ferring), a rectally-administered,
live fecal microbiota suspension, for
prevention of additional recurrences of Clostridioides
difficile infection (CDI) following antibiotic treatment
for a recurrent episode of CDI in adults. Rebyota is
the first microbiome-based treatment to be approved
for this indication. It is not approved for initial
treatment of CDI. Fecal microbiota transplantation
(FMT) has been used in patients with multiple
CDI recurrences.